Brandes Investment Partners LP Has $38.76 Million Stake in Smith & Nephew SNATS, Inc. $SNN

Brandes Investment Partners LP decreased its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 5.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,181,183 shares of the medical equipment provider’s stock after selling 69,014 shares during the quarter. Brandes Investment Partners LP owned about 0.28% of Smith & Nephew SNATS worth $38,755,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Paradigm Asset Management Co. LLC acquired a new stake in shares of Smith & Nephew SNATS during the 3rd quarter worth approximately $1,502,000. Todd Asset Management LLC bought a new stake in Smith & Nephew SNATS during the 3rd quarter valued at $26,319,000. Citigroup Inc. increased its stake in Smith & Nephew SNATS by 44.8% during the 3rd quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider’s stock valued at $17,661,000 after purchasing an additional 150,517 shares in the last quarter. Factory Mutual Insurance Co. bought a new stake in Smith & Nephew SNATS during the 3rd quarter valued at $1,007,000. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Smith & Nephew SNATS during the 3rd quarter valued at $16,501,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Price Performance

SNN opened at $31.34 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average price is $31.36 and its two-hundred day moving average price is $32.87. Smith & Nephew SNATS, Inc. has a 1 year low of $28.40 and a 1 year high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last posted its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, equities analysts anticipate that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Kepler Capital Markets lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Canaccord Genuity Group decreased their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Finally, Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Smith & Nephew SNATS presently has an average rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.